Profile data is unavailable for this security.
About the company
Eurofins Scientific SE is a Luxembourg-based company engaged in the business support services industry. The Company joins a part of international group of laboratories providing a range of analytical testing services to the pharmaceutical, food, environmental and, consumer products industries and to governments. It operates through a number of subsidiaries, such as VRL Laboratories in the United States, Institut Nehring GmbH in Germany, Agfirst Bay of Plenty, a fruit maturity testing laboratory in New Zealand, and Megalab SA, a clinical diagnostic laboratory in Spain.
- Revenue in EUR (TTM)6.76bn
- Net income in EUR662.20m
- Incorporated2012
- Employees65.69k
- LocationEurofins Scientific SE23 val FleuriLUXEMBOURG 1526LuxembourgLUX
- Websitehttps://www.eurofins.com/
More ▼
Mergers & acquisitions
| Acquired company | ERF:PAR since announced | Transaction value |
|---|---|---|
| Ac.Biomed GmbH | 9.83% | -- |
| Planton GmbH | 21.55% | -- |
Data delayed at least 15 minutes, as of Mar 02 2026 16:35 GMT.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BB BIOTECH AG | 1.03bn | 636.48m | 2.87bn | 73.00 | 4.49 | 0.9348 | -- | 2.78 | 10.49 | 10.49 | 17.10 | 50.39 | 0.3614 | -- | 340.35 | 12,854,030.00 | 22.27 | -2.09 | 22.83 | -2.27 | 99.99 | 96.50 | 61.61 | -81.41 | -- | 2.75 | 0.00 | -- | 449.50 | -3.62 | 661.71 | -3.51 | -- | -8.97 |
| Zealand Pharma A/S | 1.23bn | 863.88m | 3.48bn | 481.00 | 4.05 | 1.73 | 4.01 | 2.82 | 89.72 | 89.72 | 130.26 | 210.04 | 0.724 | 0.1524 | 95.05 | 19,157,710.00 | 50.72 | 12.33 | 52.94 | 13.28 | 99.99 | 99.61 | 70.05 | 30.02 | 23.57 | -- | 0.0266 | 0.00 | 14,598.86 | 116.89 | 698.34 | -- | 22.50 | -- |
| Bachem Holding Ltd | 746.36m | 147.74m | 4.90bn | 2.29k | 33.06 | 3.27 | 25.67 | 6.57 | 1.80 | 1.80 | 9.07 | 18.14 | 0.3733 | 1.05 | 4.37 | 307,174.00 | 7.39 | 8.26 | 8.60 | 9.44 | 31.23 | 31.55 | 19.79 | 20.06 | 0.781 | 12.09 | 0.0428 | 52.54 | 4.84 | 14.05 | 7.50 | 17.29 | 56.91 | 7.21 |
| Abivax SA | 0.00 | -195.39m | 8.11bn | 69.00 | -- | -- | -- | -- | -3.09 | -3.09 | 0.00 | -0.7607 | 0.00 | -- | -- | 0.00 | -96.69 | -65.05 | -184.49 | -98.10 | -- | -- | -- | -- | -- | -21.71 | 2.33 | -- | -- | -- | -19.29 | -- | -7.33 | -- |
| Qiagen NV | 1.77bn | 359.67m | 8.64bn | 5.65k | 24.80 | 2.84 | 16.49 | 4.88 | 1.69 | 1.69 | 8.30 | 14.77 | 0.3488 | 2.66 | 5.45 | 312,919.50 | 7.09 | 5.89 | 7.77 | 6.96 | 62.97 | 63.60 | 20.33 | 17.13 | 3.31 | -- | 0.3045 | -- | 5.65 | 2.25 | 408.28 | 3.42 | -7.40 | -- |
| Eurofins Scientific SE | 6.76bn | 662.20m | 12.42bn | 65.69k | 19.19 | 2.65 | 9.16 | 1.84 | 3.55 | 2.20 | 36.23 | 25.71 | 0.6177 | 36.38 | 4.79 | 102,842.00 | 6.63 | 7.27 | 8.41 | 9.08 | 24.29 | 23.69 | 10.74 | 11.01 | 1.03 | 8.55 | 0.492 | 23.70 | -2.80 | 4.43 | 4.37 | -0.2934 | 8.58 | 1.15 |
| Genmab A/S | 3.15bn | 815.07m | 15.87bn | 3.03k | 18.93 | 3.08 | 18.14 | 5.04 | 97.53 | 97.53 | 374.75 | 600.11 | 0.3858 | 17.63 | 3.66 | 7,767,051.00 | 9.99 | 14.22 | 11.25 | 15.57 | 93.60 | 96.72 | 25.89 | 31.44 | 2.01 | -- | 0.4813 | -- | 19.19 | 19.19 | -15.00 | 5.77 | 3.22 | -- |
| argenx SE | 3.51bn | 1.09bn | 40.63bn | 1.60k | 39.73 | -- | -- | 11.56 | 16.52 | 16.52 | 53.22 | -- | -- | -- | -- | -- | -- | -- | -- | -- | 89.15 | -- | 31.12 | 8.40 | -- | -- | -- | -- | 89.54 | 151.52 | 55.10 | -- | -- | -- |
| Lonza Group AG | 7.19bn | 1.00bn | 41.46bn | 19.77k | 41.44 | 4.03 | 24.20 | 5.77 | 12.94 | 13.51 | 93.02 | 133.07 | 0.3375 | 2.45 | 4.32 | 330,332.30 | 4.70 | 4.70 | 5.78 | 5.72 | 36.15 | 37.28 | 13.92 | 13.02 | 1.77 | 7.77 | 0.313 | 34.17 | -0.6541 | 7.70 | 42.92 | 4.48 | 7.13 | 10.76 |
Data as of Mar 02 2026. Currency figures normalised to Eurofins Scientific SE's reporting currency: Euro EUR
15.47%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 04 Feb 2026 | 4.26m | 2.34% |
| Harris Associates LPas of 31 Dec 2025 | 3.70m | 2.03% |
| Rothschild & Co Wealth Management (UK) Ltd.as of 31 Dec 2025 | 3.26m | 1.79% |
| Ruane, Cunniff & Goldfarb LPas of 31 Dec 2025 | 2.92m | 1.60% |
| 1832 Asset Management LPas of 30 Nov 2025 | 2.68m | 1.47% |
| Capital International Ltd.as of 05 Feb 2026 | 2.51m | 1.38% |
| BlackRock Fund Advisorsas of 06 Feb 2026 | 2.48m | 1.36% |
| Norges Bank Investment Managementas of 30 Jun 2025 | 2.32m | 1.27% |
| First Pacific Advisors LPas of 06 Feb 2026 | 2.05m | 1.13% |
| RBC Global Asset Management (UK) Ltd.as of 31 Dec 2025 | 2.00m | 1.10% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
